Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 11/20 | 0.55 |
| ▸ | RARG | P13631 | 11/20 | 0.55 |
| ▸ | RARA | P10276 | 7/20 | 0.55 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.55 |
| ▸ | RXRA | P19793 | 9/20 | 0.38 |
| ▸ | RXRB | P28702 | 8/20 | 0.38 |
| ▸ | RXRG | P48443 | 6/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.35 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8901695 | 0.80 | RARB (0.59) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL14257543 | 0.79 | RARB (0.58) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL4373673 | 0.79 | RARB (0.58) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL6664854 | 0.79 | RARB (0.61) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL9006923 | 0.79 | RARB (0.46) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL4517661 | 0.77 | RARB (0.39) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL6472676 | 0.77 | RARB (0.35) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL6239982 | 0.77 | RARB (0.39) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL9484589 | 0.77 | RARB (0.65) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL9483828 | 0.76 | RARB (0.63) | RARBRARGRARACYP26A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144783-A1 | SYNTHETIC RETINOIDS FOR USE IN RAR ACTIVATION | UNIVERSITY OF DURHAM (GB) | 2022-05-12 | — | — | US | disclosed |
| US-8293803-B2 | Retinoid compounds and their use | REINNERVATE LIMITED (GB) | 2012-10-23 | — | — | US | disclosed |
| US-20100093088-A1 | RETINOID COMPOUNDS AND THEIR USE | REINNERVATE LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| EP-2130908-A2 | Retinoid compounds and their use | REINNERVATE LIMITED (GB) | 2009-12-09 | — | — | EP | disclosed |
| EP-2054504-A2 | RETINOID COMPOUNDS AND THEIR USE | REINNERVATE LIMITED (GB) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008025965-A2 | RETINOID COMPOUNDS AND THEIR USE | REINNERVATE LIMITED (GB) | 2008-03-06 | — | — | WO | disclosed |
| US-7259187-B2 | Tropolone derivatives | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2007-08-21 | — | — | US | disclosed |
| US-6368608-B1 | SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHE DERMATOLOGIQUES GALDERMA (C.I.R.D.) (FR) | 2002-04-09 | — | — | US | disclosed |
| US-6326510-B1 | SKIN DISORDERS; ANTICANCER AGENTS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (FR) | 2001-12-04 | — | — | US | disclosed |
| US-6162445-A | Polyaromatic propynyl compounds and pharmaceutical/cosmetic compositions comprised thereof | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2000-12-19 | — | — | US | disclosed |
| EP-0901462-A1 | BI-AROMATIC COMPOUNDS, COMPOSITIONS CONTAINING THEM AND USES | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, ( CIRD GALDERMA) (FR) | 1999-03-17 | — | — | EP | disclosed |
| WO-1998034909-A1 | BI-AROMATIC COMPOUNDS, COMPOSITIONS CONTAINING THEM AND USES | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 1998-08-13 | — | — | WO | disclosed |
| EP-0661258-B1 | Biaromatic propynyl compounds, pharmaceutical compositions and cosmetics containing them and their uses | CIRD GALDERMA (FR) | 1998-04-08 | — | — | EP | disclosed |
| EP-0661258-A1 | Biaromatic propynyl compounds, pharmaceutical compositions and cosmetics containing them and their uses | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, ( CIRD GALDERMA) (FR) | 1995-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144783-A1 | SYNTHETIC RETINOIDS FOR USE IN RAR ACTIVATION | RARA, RXRA, RARB | RARB 3/4885RARG 4/4885RARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.